- Home
- KRNT vs GYRE Comparison
KRNT vs GYRE Comparison
Compare KRNT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNT
- GYRE
- Stock Information
- Founded
- KRNT 2002
- GYRE 2002
- Country
- KRNT Israel
- GYRE United States
- Employees
- KRNT N/A
- GYRE N/A
- Industry
- KRNT Industrial Machinery/Components
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- KRNT Industrials
- GYRE Health Care
- Exchange
- KRNT Nasdaq
- GYRE Nasdaq
- Market Cap
- KRNT 893.9M
- GYRE 897.1M
- IPO Year
- KRNT 2015
- GYRE N/A
- Fundamental
- Price
- KRNT $20.29
- GYRE $7.20
- Analyst Decision
- KRNT Strong Buy
- GYRE
- Analyst Count
- KRNT 5
- GYRE 0
- Target Price
- KRNT $33.20
- GYRE N/A
- AVG Volume (30 Days)
- KRNT 206.5K
- GYRE 178.6K
- Earning Date
- KRNT 08-06-2025
- GYRE 08-12-2025
- Dividend Yield
- KRNT N/A
- GYRE N/A
- EPS Growth
- KRNT N/A
- GYRE N/A
- EPS
- KRNT N/A
- GYRE 0.02
- Revenue
- KRNT $206,506,000.00
- GYRE $100,643,000.00
- Revenue This Year
- KRNT $10.86
- GYRE $21.04
- Revenue Next Year
- KRNT $12.68
- GYRE $89.64
- P/E Ratio
- KRNT N/A
- GYRE $89.89
- Revenue Growth
- KRNT N/A
- GYRE N/A
- 52 Week Low
- KRNT $13.59
- GYRE $6.11
- 52 Week High
- KRNT $34.29
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- KRNT 56.45
- GYRE 44.34
- Support Level
- KRNT $19.28
- GYRE $7.37
- Resistance Level
- KRNT $20.36
- GYRE $7.80
- Average True Range (ATR)
- KRNT 0.57
- GYRE 0.44
- MACD
- KRNT 0.17
- GYRE 0.05
- Stochastic Oscillator
- KRNT 100.00
- GYRE 49.43
About KRNT Kornit Digital Ltd.
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.